(b)(4).
To date the device has not been returned.
If the device or further details are received at a later date a supplemental medwatch will be sent.
Attempts are being made to obtain the following information.
To date no response has been provided.
If further details are received at a later date a supplemental medwatch will be sent.
The patient demographic info: weight, bmi at the time of index procedure were there any pre-existing signs/symptoms of active infection prior to this surgical procedure? were cultures performed? results? product code and lot #.
Does the surgeon believe that the ethicon product (prolene mesh) involved caused and/or contributed to the post-operative complications described? does the surgeon believe there was any deficiency with the ethicon product involved? what is the patient's current status? if information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.
|
It was reported that a patient underwent an eventrorraphy procedure on (b)(6) 2020 and the mesh was implanted.
It was reported that on (b)(6) 2020, the patient reported feeling well, with controlled pain, no fever, no emesis, satisfactory evolution.
It was also reported that on (b)(6) 2020, the patient indicated that she had pain after surgical intervention associated with heat, redness and erythema, the day before she removed the drain.
It was also reported that the patient had new paraclinics performed with pcr 22.
26, hb: 10.
4, platelets: 516000.
It was reported that antibiotic treatment was started with cefazolin 2 g / 6 hours, tramadol 50 mg / 8 h, dipyrone 1 g / 8 h.
It was reported that on (b)(6) 2020 the patient continued with the same management.
It was reported that a review by a surgeon on (b)(6) 2020 indicated iso, with improvement in pain and heat, and collection was discarded.
It was reported that enoxaparin 40 mg / sc / day was added.
It was also reported that on (b)(6) 2020 a review by a surgeon indicated no peritoneal irritation, surgical wound in good condition, no secretions or bleeding.
It was reported that with symptomatic and clinical improvement patient was given recommendations, warning signs, order of oral antibiotic, discharge and control appointment.
(cephalexin 500 mg / 6 hours for 5 days).
|